Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

ting GI problems, no clinically relevant drug-related adverse events or changes in laboratory safety parameters were observed.

"Prolonged courses of stable disease with minimal to no toxicity are encouraging signs", said Dr. Von Hoff. "The applications for an oral agent with these mechanisms of action are numerous."

Paul Blake, MD, AEterna Zentaris Senior Vice President and Chief Medical Officer added, "We are pleased with these Phase 1 results on AEZS-112, which indicate the potential for safe combination with other anticancer drugs. We now look forward to working on the further development of AEZS-112 in collaboration with our expert investigators."

About the AEZS-112 Phase 1 Study

This open-label, dose-escalation, multi-center, intermittent treatment Phase 1 study included patients with advanced solid tumors and lymphoma who had either failed standard therapy or for whom no standard therapy existed. Patients received a once-a-week oral administration of AEZS-112 for three consecutive weeks, followed by a one-week period without treatment. The cycles were repeated every four weeks based on tolerability and response, basically planned for up to four cycles, but allowing for continuation in case of potential benefit for the patient. The starting dose of AEZS-112 in this study was 13 mg/week, with doubling of doses in subsequent cohorts in the absence of significant toxicity. Primary endpoints of the Phase 1 trial focused on determining the safety and tolerability of AEZS-112 (maximum tolerated dose, MTD), as well as establishing a recommended Phase 2 dose and regimen. Secondary endpoints aimed at establishing the pharmacokinetics and determining the efficacy based on standard response criteria.

Preliminary results from this study were presented recently at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado. Poster #5567 entitled, "Phase I dose-escalation, safety, and pharma
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... effect in bilayer graphene and shown that this exotic ... field. , The fractional quantum Hall effect, which ... exposed to large magnetic fields, is a striking example ... as a single system. However, while the basic theory ... this collective behavior remain not well understood, in part ...
(Date:7/10/2014)... sit upside down forever. Nanophysics makes sure of that. Mechanics ... just published in Physical Review E . Knowledge that ... that seem to be able to sit still forever, and ... years. We will soon be able to buy smart new ... But the fact is, sooner or later the grip is ...
(Date:7/10/2014)... University of Illinois at Urbana-Champaign provides new insights ... spin and heat at the nanoscale, and addresses ... data storage and information processing. , "Electrons ... In a typical charge current, electrons, spin-angular-momentum is ... David Cahill, a professor of materials science and ...
(Date:1/15/2014)... to assembling a club sandwich at the nanoscale, ... have succeeded in crafting a uniform, multi-walled carbon-nanotube-based ... commonly used in upholstered furniture and other soft ... foam was reduced 35 percent compared with untreated ...
Breaking Biology Technology:Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Even geckos can lose their grip 2University of Illinois study advances limits for ultrafast nano-devices 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... Currently, some 20 percent of the world,s industrial production ... the pace of chemical reactions by factors of billions. ... by catalysts. Many are hoping to ... consumption and less pollution. Highly active and selective nanocatalysts, ...
... 20, 2011 TEI Biosciences today announced that ... CEO, is an Ernst & Young Entrepreneur Of ... semifinalist. The program recognizes entrepreneurs who demonstrate excellence ... financial performance, and personal commitment to their businesses ...
... Ariz., April 20, 2011 ... the U.S.-grown guayule plant as a replacement for traditional ... the residual agricultural materials are utilized as a feedstock ... responsible and carbon neutral, resulting in a new generation ...
Cached Biology Technology:UCLA researchers now 1 step closer to controlled engineering of nanocatalysts 2TEI Biosciences Chairman, President and CEO Yiannis Monovoukas Named Ernst & Young Entrepreneur Of The Year® 2011 New England Award Semifinalist 2Every Day is Earth Day for Yulex Corporation 2
(Date:7/11/2014)... Mineral Research awarded Michael F. Holick, PhD, MD, of ... Louis V. Avioli Award. Holick, a professor of medicine, ... revolutionizing the understanding of vitamin D and its role ... member of the American Society for Bone and Mineral ... basic research. It is named for ASBMR,s first president ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... the Max Planck Institute for Medical Research in Heidelberg, ... photosynthesis, the process by which the Earth first gained ... which is therefore crucial for all higher forms of ... first direct visualization of a crucial event in the ... protein complex, photosystem II, splits water into hydrogen and ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2A first direct glimpse of photosynthesis in action 2
... clinical trial of a recombinant vaccine for the deadly ... indicate the vaccine is safe and effective in eliciting ... , The nearly year-long pilot study involved three groups ... a series of three injections of various doses of ...
... Researchers at the San Francisco VA Medical Center have uncovered ... grow in response to blocked arteries. , A team led ... in mice that the MMP2 gene is essential for the ... blocked. , The team also identified and described, for ...
... Researchers at the U.S. Department of Energy's Brookhaven National ... browser and database of the brain of a popular ... around the world can now download these extremely accurate ... -- such as which parts of the brain are ...
Cached Biology News:Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 2Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 3Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 4Genetic key to growth of new arteries is identified 2Genetic key to growth of new arteries is identified 3
... 20 System revolutionizes DNA sequencing, delivering sequence ... The Genome Sequencer 20 System includes: ... consumables for library construction, amplification, and sequencing ... novo assembly The instrument ...
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... demonstrated that oxidative stress is involved in ... stress is the condition in which an ... exist leading to the damage of a ... stress is through several antioxidant systems4 that ...
Biology Products: